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Isoniazid plus antiretroviral therapy to prevent tuberculosis: 
a randomised double-blind, placebo-controlled trial
Molebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, Judith R Glynn, Katherine Fielding, Gilles van Cutsem, Katalin A Wilkinson, 
Rene Goliath, Shaheed Mathee, Eric Goemaere, Gary Maartens
Summary
Background Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with 
HIV than in people without HIV. We aimed to assess the eﬀ ect of isoniazid preventive therapy on the risk of 
tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.
Methods For this pragmatic randomised double-blind, placebo-controlled trial in Khayelitsha, South Africa, we 
randomly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be 
completed during 15 months). Randomisation was done with random number generator software. Participants, 
physicians, and pharmacy staﬀ  were masked to group assignment. The primary endpoint was time to development of 
incident tuberculosis (deﬁ nite, probable, or possible). We excluded tuberculosis at screening by sputum culture. We 
did a modiﬁ ed intention-to-treat analysis and excluded all patients randomly assigned to groups who withdrew before 
receiving study drug or whose baseline sputum culture results suggested prevalent tuberculosis. This study is 
registered with ClinicalTrials.gov, number NCT00463086.
Findings 1329 participants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667) 
between Jan 31, 2008, and Sept 31, 2011, and contributed 3227 person-years of follow-up to the analysis. We 
recorded 95 incident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2·3 per 100 person-
years, 95% CI 1·6–3·1), and 58 in the placebo group (3·6 per 100 person-years, 2·8–4·7; hazard ratio [HR] 0·63, 
95% CI 0·41–0·94). Study drug was discontinued because of grade 3 or 4 raised alanine transaminase concentrations 
in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 individuals in the placebo group 
(risk ratio 1·9, 95% CI 0·90–4·09). We noted no evidence that the eﬀ ect of isoniazid preventive therapy was restricted 
to patients who were positive on tuberculin skin test or interferon gamma release assay (adjusted HR for patients 
with negative tests 0·43 [0·21–0·86] and 0·43 [0·20–0·96]; for positive tests 0·86 [0·37–2·00] and 0·55 [0·26–1·24], 
respectively). 
Interpretation Without a more predictive test or a multivariate algorithm that predicts beneﬁ t, isoniazid preventive 
therapy should be recommended to all patients receiving antiretroviral therapy in moderate or high incidence areas 
irrespective of tuberculin skin test or interferon gamma release assay status.
Funding Department of Health of South Africa, the Wellcome Trust, Médecins Sans Frontières, European and 
Developing Countries Clinical Trials Partnership, Foundation for Innovation and New Diagnostics, the European 
Union, and Hasso Plattner (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town).
Introduction
Tuberculosis is the main cause of morbidity and mortality 
in people infected with HIV-1. The burden is greatest in 
sub-Saharan Africa, especially in southern Africa where 
more than 50% of new tuberculosis cases are co-infected 
with HIV-1.1 Findings of a meta-analysis2 of randomised 
controlled trials showed that isoniazid preventive therapy 
decreased the risk of tuberculosis by 32% in people with 
HIV-1 who were not on combination antiretroviral 
therapy. Strong statistical evidence for beneﬁ t was only 
reported in individuals who had positive tuberculin skin 
tests. However, there was heterogeneity of isoniazid 
preventive therapy duration and follow-up between the 
included studies. Antiretroviral therapy independently 
reduces the risk of tuberculosis by 65%,3 but tuberculosis 
is more common in people infected with HIV than in 
people without HIV.4
Data from three retrospective observational cohort 
studies5–7 suggested a greater eﬀ ect of combined anti-
retroviral therapy and isoniazid preventive therapy on the 
risk of tuberculosis than antiretroviral therapy alone. The 
proportion of individuals who received both treatments 
concurrently was unclear in the Brazilian study,6 and 
isoniazid preventive therapy preceded antiretroviral 
therapy in the South African study.7 In the BOTUSA 
randomised controlled trial8 done in Botswana, isoniazid 
preventive therapy for 36 months was more beneﬁ cial 
than treatment for 6 months in individuals who started 
antiretroviral therapy. However, antiretroviral therapy was 
prescribed in some of the participants at diﬀ erent times 
during follow-up when participants fulﬁ lled criteria for 
antiretroviral therapy initiation. Thus, the independent 
eﬀ ect of isoniazid preventive therapy in patients on 
antiretroviral therapy could not be established. In an 
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Indian study,9 in which the eﬀ ect of 6 months of 
ethambutol and isoniazid was compared with 36 months 
of isoniazid in patients with HIV, some participants 
started antiretroviral therapy, but the eﬀ ect of concomitant 
antiretroviral therapy and isoniazid preventive therapy on 
eﬃ  cacy and toxic eﬀ ects was not reported.
Concurrent isoniazid preventive therapy and anti-
retroviral therapy could result in shared toxic eﬀ ects, 
notably hepatitis and neuropathy. Furthermore, isoniazid 
inhibits several cytochrome P450 isoenzymes,10 which 
metabolise many antiretroviral drugs. This inhibition can 
cause increased antiretroviral concentrations, which might 
exceed the toxic threshold. Therefore, whether isoniazid 
preventive therapy further reduces the risk of tuberculosis 
in people on antiretroviral therapy is important to establish, 
and any additional toxic eﬀ ects should be quantiﬁ ed.
We aimed to assess the eﬀ ect of isoniazid preventive 
therapy on the risk of active tuberculosis in people with 
HIV-1 concurrently receiving antiretroviral therapy. Our 
secondary objectives were to establish toxic eﬀ ects of 
treatment and all-cause mortality.
Methods
Study design and participants
We did a pragmatic individually randomised double-
blind, placebo-controlled trial between Jan 31, 2008, and 
Sept 31, 2011, of isoniazid preventive therapy in people 
with HIV-1 on antiretroviral therapy at the Ubuntu clinic 
in Khayelitsha, Cape Town, South Africa.
Adults (≥18 years) were recruited among antiretroviral 
therapy clinic attendees consecutively listed in study 
screening logs. All participants had baseline tuberculosis 
symptom screening and sputum mycobacterial culture.11 
Exclusion criteria were active tuberculosis or suspicion of 
active tuberculosis as established by symptom screening, 
present or previous treatment of latent tuberculosis 
infection; present treatment with ﬂ uoroquinolones or 
other antibiotics with marked antituberculous activity, 
history of intolerance to isoniazid; grade 3 or 4 baseline 
alanine transaminase, grade 3 or 4 peripheral neuropathy, 
pregnancy, or less than 6 weeks post partum. We used 
tables from the AIDS Clinical Trials Group12 to grade 
toxic eﬀ ects of treatment for people on antiretroviral 
therapy.
Ethics approval was obtained from the ethics review 
boards of the University of Cape Town, Médecins Sans 
Frontières, and the London School of Hygiene & Tropical 
Medicine. Written consent or a thumb-print was needed 
from all participants before screening. Four people on a 
data safety and monitoring board provided oversight 
during the study.
Randomisation and masking
Patients were randomly assigned (1:1) to receive daily 
self-administered isoniazid or matching placebo dosed 
according to bodyweight (200 mg per day for <50 kg 
or 300 mg per day for ≥50 kg) together with 25 mg of 
pyridoxine for 12 months (could be completed 
during 15 months). Randomisation was by random 
number generator software (in Excel) and was stratiﬁ ed 
by antiretroviral therapy status at baseline: just started 
antiretroviral therapy (start-antiretroviral therapy) versus 
established on antiretroviral therapy (on-antiretroviral 
therapy). Partici pants, clinicians, and local pharmacy 
staﬀ  were masked to treatment allocations. The appendix 
gives further details on randomisation and masking.
Procedures
At each visit participants were asked about symptoms of 
adverse drug events: nausea, vomiting, or right upper-
quadrant pain, rashes, and new or worsening peripheral 
neuropathy. During the intervention phase, we 
measured alanine trans aminase concentration at 
baseline, every month for the ﬁ rst 3 months, and 
every 3 months thereafter. Protocol-speciﬁ ed reasons 
for permanent cessation of study drug because toxic 
eﬀ ects were new or worsening peripheral neuropathy of 
grade 2 or more, grade 3 or 4 raised alanine transaminase 
concentrations, or clinical hepatitis, new rash grade 2 or 
more. CD4 lymphocyte counts and viral loads were 
measured according to clinic protocols (initially 
every 6 months then every year after the ﬁ rst year on 
antiretroviral therapy from 2010). Clinic nurses and 
doctors followed up participants routinely according to 
regular clinic schedules; schedules were aligned with 
antiretroviral therapy appointments to aid participant 
retention. Pharmacy staﬀ  dispensed the study drug 
along with other routine prescriptions. Pharmacy reﬁ ll 
records were used to monitor adherence to antiretroviral 
therapy and the study drug.
A standard tuberculosis symptom screen was done at 
each clinic visit. Two sputum specimens were obtained 
from suspected cases of tuberculosis for microscopy by 
auramine staining and for mycobacterial culture. 
Species identiﬁ cation and drug sensitivity testing for 
isoniazid and rifampicin was done for all positive 
isolates (BACTEC mycobacterial growth indicator tube, 
Becton Dickinson Microbiology Systems, Cockeysville, 
MD, USA). Specimens were processed at the National 
Health Laboratory Service, Cape Town, South Africa. 
Sputum induction was done on individuals unable to 
expectorate spontaneously. Needle aspiration biopsy 
was done in patients who presented with suspected 
tuberculosis lymphadenitis. Patients suspected to have 
extrapulmonary tuberculosis and needing further 
investigation were referred to an HIV specialist clinic 
(G F Jooste Hospital, Cape Town, South Africa). Urine 
for acid fast bacilli smear and culture was requested 
from all participants with suspected extrapulmonary 
tuberculosis. Infectious disease specialists (GM and 
RJW) were consulted for diﬃ  cult cases. Tuberculosis 
treatment was started for all patients who met the case 
deﬁ nition for tuberculosis (deﬁ nite if compatible 
clinical features plus culture positive for Mycobacterium 
See Online for appendix
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tuberculosis, probable if based on microscopy, or possible 
if based only on radiology or clinical features). At each 
clinic visit, participants were asked about tuberculosis 
investigations or treatment initiated outside the Ubuntu 
clinic. The provincial electronic tuberculosis register 
and the database of the National Health Laboratory 
Service were searched at study closure for tuberculosis 
cases to verify completeness of ascertainment and to 
identify cases diagnosed at other sites in patients who 
might have left care. Database linking was done via a 
unique patient number or national identity number. All 
incident cases were veriﬁ ed before study unmasking. 
A tuberculin skin test (2TU RT23 PPD, Statens Serum 
Institut, Denmark) and interferon gamma release assay 
(QuantiFERON gold in-tube, Cellestis, Australia) were 
done as part of a nested study.13 These tests were done at 
the baseline screening visit, before application of speciﬁ c 
inclusion and exclusion criteria, and in participants who 
suggested willingness to return for tuberculin skin test 
results. Manufacturer’s criteria for interferon gamma 
release assay positivity were used (≥0·35 IU/mL); 
tuberculin skin test induration of 5 mm or more was 
deemed positive.
Outcomes
The primary endpoint was time to development of 
incident tuberculosis (deﬁ nite, probable, or possible) 
during the study. Secondary endpoints were time to death 
or the risk of adverse drug reaction. For the primary 
outcome we calculated person-time at risk from date of 
randomisation to earliest of tuberculosis (the clinic visit 
date tuberculosis was diagnosed and registered in the 
clinic database or notiﬁ ed in the tuberculosis register); 
death (death ascertainment was by report to the clinic staﬀ  
and augmented from the national death register); loss to 
follow-up (participants were deﬁ ned as lost to follow-up if 
their last clinic contact was more than 6 months before 
the date of closure of the study database, which was 
censored at their last contact date); transferred out 
(excluding participants transferred out for care at another 
clinic in the district since outcome data is available on the 
province-wide patient electronic register and from the 
national tuberculosis register); or study closure.
Statistical analysis
Results of this trial were reported in accordance with the 
CONSORT guidelines for reporting pragmatic trials.14 We 
did a modiﬁ ed intention-to-treat analysis; we excluded any 
participants who withdrew from the study before receiving 
the study drug or those whose baseline sputum culture 
results suggested prevalent tuberculosis after 
randomisation. We used the log-rank test to compare 
survival curves by treatment group. The hazard ratio (HR) 
for the treatment eﬀ ect and the associated 95% CIs were 
calculated by Cox proportional hazards regression. To 
assess the durability of the treatment eﬀ ect, follow-up time 
was split into three time groups (0–11 months, 
12–23 months, and ≥24 months) and we used the likelihood 
ratio test to test for eﬀ ect modiﬁ cation by time interval. At 
the time of the analysis, we speciﬁ ed the eﬀ ects of isoniazid 
by time since randomisation and by tuberculosis infection 
status at enrolment. Time from randomisation to death 
was compared by study group and HRs were calculated 
from the Cox proportional hazards model.
A ﬁ nal sample size of 1368 had 80% power to detect 
a 35% reduction in the incidence of tuberculosis in the 
intervention versus control group assuming a rate 
of 8·5 per 100 person-years in the control group, a type I 
error of 0·05 and a 30% loss to follow-up in each group 
(appendix).15,16 All analyses were done with STATA 
(version 12.0).
This study is registered with ClinicalTrials.gov, number 
NCT00463086.
Figure 1: Trial proﬁ le
ART=antiretroviral therapy. Start-ART=just started ART. On-ART=established on ART. *Reasons for 
excluding 291 individuals that did not meet the inclusion criteria: 211 prevalent tuberculosis diagnosed, 13 previous 
isoniazid preventive therapy, 19 pregnancy, 23 pre-existing grade 3 toxicity (alanine transaminase concentration, 
peripheral neuropathy, or rash), one younger than 18 years, 24 already on tuberculosis treatment. †Drug toxic eﬀ ects 
include: alanine transaminase grade 3 or worse, clinical hepatitis, grade 2 or worse rash or peripheral neuropathy.
2138 patients assessed for eligibility
769 excluded
 291 did not meet inclusion 
  criteria*
 394 declined to participate
 84 other reasons
Pre-specified exclusions
22 culture-positive prevalent 
  tuberculosis 
Pre-specified exclusions
17 culture-positive prevalent 
  tuberculosis 
 1 randomised but study drug 
  not received
689 assigned to placebo
 181 start-ART group
 508 on-ART group
689 received allocated intervention 
 0 did not receive study drug
680 assigned to isoniazid
 207 start-ART group
 473 on-ART group
679 received allocated intervention 
 1 did not receive study drug
Final participant outcomes
469 no event (455 completed 
  intervention phase)
 58 tuberculosis 
 18 drug toxic eﬀects†
 21 died 
 43 transferred out 
 71 lost to follow-up
Final participant outcomes
482 no event (464 completed 
  intervention phase)
 37 tuberculosis  
 27 drug toxic eﬀects†
 16 died 
 40 transferred out 
 71 lost to follow-up 
662 included in modiﬁed 
  intention-to-treat analysis
 200 start-ART group
 462 on-ART group
667 included in modiﬁed 
  intention-to-treat analysis 
 177 start-ART group
 490 on-ART group
1369 randomised
 388 start-ART group
 981 on-ART group
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Screening started on Nov, 1, 2007, the ﬁ rst participant was 
randomised on Jan 31, 2008, and the last completed the 
study drug on Oct 31, 2010, and study closure was on 
Sept 31, 2011. Of 2138 individuals with HIV assessed for 
eligibility, 1369 participants were enrolled in the study and 
randomly assigned to receive either placebo or isoniazid 
(ﬁ gure 1). The appendix shows characteristics at screening 
of the 478 participants who were screened but not randomly 
assigned, and the 1369 (64%) who were. The proportion of 
participants already established on antiretroviral therapy 
was lower in individuals not randomly assigned and the 
proportion with previous tuberculosis was higher in those 
randomly assigned (42·2% vs 34·5%). 39 culture-positive 
prevalent tuberculosis cases were diagnosed after 
randomisation, and one person did not receive the study 
drug, leaving 1329 in the modiﬁ ed intention-to-treat 
analysis; 667 received placebo and 662 received isoniazid. 
Baseline characteristics at enrolment for those in the 
modiﬁ ed intention-to-treat analysis were similarly 
distributed between the study groups (table 1). The median 
time on antiretroviral therapy was 357 days (IQR: 139–798 in 
the on-antiretroviral therapy group and 14 days (IQR: 4–25) 
in the start-antiretroviral therapy group. The appendix 
provides reasons for why placebo or isoniazid was stopped 
during the active intervention phase by study group. The 
maximum follow-up was 3·7 years, with a median 
of 2·5 years (IQR 2·1–3·1). Numbers of patients at study 
closure who transferred out or were lost to follow-up were 
similar between study groups. The proportion lost to 
follow-up in each group was 11%; far less than the 30% 
initially assumed (ﬁ gure 1).
For participants in each group who completed 12 months 
of the study drug (n=1100), a median of 360 doses 
(IQR 330–390) were dispensed during a median 
of 12 months on the study drug (IQR 11–13 months; 
appendix). We recorded no diﬀ erence in median months 
on study drug and total doses dispensed between study 
groups.
95 cases of tuberculosis developed during 3226·5 person-
years of follow-up (58 on placebo and 37 on isoniazid; 
34/95 [36%] were culture-conﬁ rmed; table 2). 56 of 95 
(59%) cases were diagnosed at the study site, 37 of 95 (39%) 
at satellite clinics, and 7 of 95 (7%) were identiﬁ ed through 
linkage to national health laboratory service and provincial 
electronic tuberculosis notiﬁ cations data. 72 of 95 (76%)
cases developed during the ﬁ rst 2 years of follow-up after 
randomisation (ﬁ gures 2–4). The overall rate of 
tuberculosis was 2·9 per 100 person-years; higher in the 
placebo group than the isoniazid group (table 2). 
Adjustment for time-updated CD4 count did not 
signiﬁ cantly change the overall HR for tuberculosis 
(HR 0·64, 95% CI 0·42–0·96). Eight of the 95 participants 
with tuberculosis subsequently died during treatment 
(two on isoniazid and six on placebo). We did drug 
sensitivity testing on 25 of the 34 culture-conﬁ rmed cases 
of tuberculosis: four had multidrug-resistant tuberculosis 
(three on placebo and one on isoniazid), and two had 
isoniazid mono-resistance (both on isoniazid).
The eﬀ ect of isoniazid on the risk of tuberculosis was 
greatest in the ﬁ rst year of follow-up when individuals 
were still on treatment (unadjusted HR 0·52, 
95%  CI 0·27–1·01; ﬁ gure 4). The eﬀ ect decreased over 
time (at 12–23 months, HR 0·61, 0·30–1·21, and 
at 24 months, HR=0·78, 95% CI 0·39–2·0). However, 
Placebo (n=667) Isoniazid (n=662) Total (n=1329)
Median age (years) 34 (29–40) 34 (30–40) 34 (30–40)
Women 498 (75%) 500 (76%) 998 (75%)
Established on ART 490 (74%) 462 (70%) 952 (72%)
Median days on ART, on- ART 330 (137–727) 394 (139–889) 357 (139–798)
Median days on ART, start- ART 14 (4–20) 14 (4–25) 14 (4–25)
Median CD4 count (cells per mm³)* 214 (154–355) 218 (150–373) 216 (152–360)
Previous tuberculosis† 271 (41%) 289 (44%) 560 (43%)
TST 
Positive (≥5 mm) 202 (30%) 190 (29%) 392 (30%)
Negative (<5 mm) 283 (42%) 269 (41%) 552 (42%)
Unknown 182 (27%) 203 (31%) 385 (29%)
IGRA 
Positive 205 (31%) 184 (28%) 389 (29%)
Negative 261 (39%) 274 (41%) 535 (40%)
Indeterminate 38 (6%) 36 (5%) 74 (6%)
Unknown 163 (24%) 168 (25%) 331 (25%)
Discordant or concordant TST/IGRA pairs
TST+/IGRA+ 119 (18%) 115 (17%) 234 (18%)
TST–/IGRA– 190 (29%) 198 (30%) 388 (29%)
TST+/IGRA– 73 (11%) 66 (10%) 139 (11%)
TST–/IGRA+ 64 (10%) 54 (8%) 118 (9%)
Unknown 221 (33%) 229 (35%) 450 (34%)
Combination ART regimen
D4T/3TC/EFV 272 (41%) 253 (38%) 525 (40%)
AZT/3TC/EFV 36 (5%) 53 (8%) 89 (7%)
D4T/3TC/NVP 223 (33%) 212 (32%) 435 (33%)
AZT/3TC/NVP 118 (18%) 130 (20%) 248 (19%)
Other‡ 18 (3%) 14 (2%) 32 (2%)
Median baseline alanine transaminase 
(IQR), IU/mL
28 (21–43) 30 (22–41) 29 (22–42)
Data are median (IQR) or n (%). ART=antiretroviral therapy. TST=tuberculin skin test. IGRA=interferon gamma release 
assay. Start-ART=just started ART. On-ART=established on ART. D4T=stavudine. AZT=azidothymidine or zidovudine. 
3TC=lamivudine. EFV=efavirenz. NVP=nevirapine. *n=602 for placebo, 585 for isoniazid, and 1187 in total. †n=657 for 
placebo, 652 for isoniazid, and 1309 in total. ‡Other ART regimens: AZT/didanosine/lopinavir/ritonavir (two on placebo), 
3TC/EFV/tenofovir (nine on placebo and 12 on isoniazid), D4T/3TC/lopinavir/ritonavir (one on placebo and one on 
isoniazid), AZT/3TC/lopinavir/ritonavir (two on placebo), 3TC/NVP/tenofovir (three on placebo and one on isoniazid), 
3TC/tenofovir/lopinavir/ritonavir (one on placebo).
Table 1: Baseline characteristics at enrolment of individuals included in modiﬁ ed intention-to-treat 
analysis, by study group
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statistical power was insuﬃ  cient to show formal 
interaction by time since randomisation (p=0·34, 
assuming linear eﬀ ect). The appendix shows tuberculosis 
rates per study period since randomisation.
Table 3 shows analyses to assess the eﬀ ect of 
antiretroviral therapy with isoniazid on time to 
tuberculosis stratiﬁ ed by tuberculin skin test or interferon 
gamma release assay status. The eﬀ ect of isoniazid on 
tuberculosis incidence was greater in participants with 
negative tuberculin skin tests or interferon gamma 
release assay than in those tested positive, but we noted 
weak statistical evidence that the eﬀ ects were diﬀ erent 
(interaction p=0·58 for tuberculin skin test and p=0·24 for 
interferon gamma release assay) after adjustment for 
baseline CD4 count and antiretroviral therapy status on 
enrolment. Participants who did not accept tuberculin 
skin test or interferon gamma release assay testing did 
not diﬀ er from those who did with respect to age, sex, 
CD4 count, previous history of tuberculosis, or 
antiretroviral therapy status (appendix).
We recorded 37 deaths from all causes during 
3579 person-years of follow-up (21 on placebo and 16 on 
isoniazid; table 2). The overall rate of all-cause mortality 
was one per 100 person-years; rates were slightly lower 
in the isoniazid (0·9 per 100 person-years) compared 
with the placebo group (1·2 per 100 person-years; 
HR 0·72, 95% CI 0·34-1·34, log-rank p=0·32; ﬁ gure 2). 
Further details on the 37 deaths were obtained from 
hospital records or family reports; eight were 
tuberculosis deaths (two isoniazid and six placebo), 
13 were due to non-tuberculosis reasons deemed 
unrelated to the study drug (six isoniazid and seven 
placebo; eight happened during the intervention phase), 
and the rest of the reasons were unknown (eight 
isoniazid and eight placebo; two happened during the 
intervention phase). The appendix provides a summary 
of speciﬁ c causes of death by study group.
We recorded no diﬀ erence between study groups in 
study drug discontinuation due to any adverse event 
(relative risk [RR] 1·1, 95% CI 0·84–1·42) or presumed 
toxic eﬀ ects (any of grade 3 or 4 alanine transaminase 
Overall Placebo Isoniazid Eﬀ ect
Events
per person-years
Rate per 
100 person-years
Events per
person-years
Rate per 100 
person-years
Events per
person-years
Rate per 100 
person-years
HRu* (95% CI)
Tuberculosis
All tuberculosis 95/3226·5 2·9 58/ 1597·2 3·6 37/1629·3 2·3 0·63†  (0·41–0·94)
Deﬁ nite 34/3226·5 1·1 22/1597·2 1·4 12/1629·3 0·7 0·54  (0·27–1·08)
Probable/possible 61/3226·5 1·9 36/ 1597·2 2·3 25/1629·3 1·5 0·68  (0·41–1·10)
Deaths
All causes 37/3579·1‡ 1·0 21/1792·8 1·2 16/1786·3 0·9 0·72  (0·34–1·34)
HRu=unadjusted hazard ratio. *HRu for isoniazid vs placebo· †p<0·05. ‡Person-years for death is higher than person-years for tuberculosis: four individuals died after 
developing tuberculosis.
 Table 2: Eﬀ ect of isoniazid on rate of tuberculosis or death
Figure 2: Time to tuberculosis from randomisation
The placebo group was given antiretroviral therapy plus placebo and the isoniazid group was given 
antiretroviral therapy plus isoniazid. Numbers show the number of participants followed up at each timepoint, 
and the numbers in parentheses show new tuberculosis cases in each period. Log-rank test p value for equality 
of survival curves=0·02.
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Figure 3: Cumulative hazard plot for antiretroviral therapy versus antiretroviral therapy plus isoniazid 
preventive therapy eﬀ ect by time since randomisation
Nelson-Aalen cumulative hazard plot on a logarithmic y-scale to show proportionality of hazards over time 
periods. HRs shown are unadjusted. Treatment ended 1 year after participants were randomly assigned. Likelihood 
ratio test for interaction of treatment group with study time p=0·61, and assuming linear trend for study time 
p=0·34. HR=hazard ratio.
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concentration, clinical hepatitis, new or worsening 
grade 2, or more rash or peripheral neuropathy; RR 1·5, 
95% CI 0·84–2·7; table 4). 34 participants had grade 3 or 
more raised alanine transaminase concentration, which 
resulted in termination of the study drug in 29 participants 
(in two participants grade 3 alanine transaminase was 
reported only in month 12 and results were obtained after 
the study drug was completed, subsequent alanine 
transaminase in three participants were all <grade 3). 
The risk of stopping the study drug because of grade 3 or 
above raised alanine transaminase alone was 2·9% on 
isoniazid compared with 1·5% on placebo (RR 1·9, 
0·90–4·09). The risk of stopping the drug was 2·8% if on 
isoniazid and 1·6% on placebo (RR 1·7, 0·72–4·12) for 
the on-antiretroviral therapy group, and 3·0 % and 1·1% 
for the start-antiretroviral therapy group (RR 2·7, 
0·54–12·98; data not shown). 
The appendix shows estimates of the numbers needed 
to treat or harm. 25 individuals on antiretroviral therapy 
need to be treated with isoniazid to prevent a case of 
tuberculosis. 100 individuals on antiretroviral therapy 
need to be treated with isoniazid to result in harm as 
deﬁ ned by participants stopping the study drug because 
of presumed toxic eﬀ ects.
Discussion
12 months of isoniazid preventive therapy independently 
reduced the incidence of tuberculosis in participants 
concurrently on antiretroviral therapy by 37% (panel). The 
risk-to-beneﬁ t ratio was favourable with the number 
needed to harm four times higher than the number 
needed to treat to beneﬁ t with isoniazid preventive therapy. 
The greatest beneﬁ t from isoniazid preventive therapy 
seemed to be in the ﬁ rst year; however, evidence was weak 
for the decreased eﬀ ect with time. Isoniazid preventive 
therapy beneﬁ t was greater in individuals who had negative 
tuberculin skin tests and interferon gamma release assays 
than those who tested positive, although statistical 
evidence for interaction was weak. Implementation of 
Overall Placebo Isoniazid Eﬀ ect
Events/n Risk Events/n Risk Events/n Risk RRu† (95% CI)
All reasons* 196/1329 14·7% 94/667 14·1% 102/662 15·4% 1·1 (0·84–1·42)
ALT ≥grade 3 29/1329 2·2% 10/667 1·5% 19/662 2·9% 1·9  (0·90–4·09)
ALT ≥grade 3, clinical hepatitis, ≥grade 2 rash 
or peripheral neuropathy 
45/1329 3·4% 18/667 2·7% 27/662 4·1% 1·5 (0·84–2·72)
Maximum time at risk=3·7 years. RRu=unadjusted risk ratio. ALT=alanine transaminase. *All reasons excluding tuberculosis.†RRu=RRu for isoniazid vs placebo. 
Table 4: Eﬀ ect of isoniazid on the risk of stopping the study drug because of adverse events 
 Placebo Isoniazid Eﬀ ect
 n Cases per 
person-years
Rate per 
100 person-years
n Cases per 
person-years
Rate per 
100 person-years
HRu* (95% CI) Pi† HRa‡ (95% CI) Pi§
Interferon gamma release assay¶
Negative 261 21/631·9 3·3 274 9/687·9 1·3 0·40 (0·18–0·87) ·· 0·43|| (0·20–0·96) ··
Positive 205 19/481·7 3·9 184 13/427·3 3·0 0·76 (0·38–1·5) 0·22 0·55 (0·26–1·24) 0·58
Tuberculin skin test**
Negative 283 27/660·0 4·1 269 11/656·3 1·7 0·41** (0·20–0·83) ·· 0·43|| (0·21–0·86) ··
Positive 202 14/496·4 2·8 190 12/461·1 2·6 0·92 (0·43–1·97) 0·13 0·86 (0·37–2·0) 0·24
HRu=unadjusted hazard ratio. HRa=adjusted hazard ratio. *HRu comparing isoniazid vs placebo. †Pi=Likelihood ratio test p value for interaction in the unadjusted model. ‡HR comparing isoniazid vs placebo, 
adjusted for CD4 cell count and antiretroviral therapy status at enrolment. §Pi=Likelihood ratio test p value for interaction in adjusted model. ¶Indeterminate interferon-gamma release assay results included 
with negatives. ||p<0·05. **Tuberculin skin test negative if induration <5 mm and positive if ≥5 mm. ††p<0·01.
Table 3: Eﬀ ect of isoniazid on the rate of all tuberculosis stratiﬁ ed by markers of Mycobacterium tuberculosis infection status at enrolment
Figure 4: Time to death from randomisation
The placebo group was given antiretroviral therapy plus placebo, and the isoniazid group was given antiretroviral 
therapy plus isoniazid. Log-rank test p value for equality of survival curves=0·32.
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isoniazid preventive therapy in an antiretroviral therapy 
clinic will probably be easier than in pre-antiretroviral 
therapy care because individuals on antiretroviral therapy 
receive regular drugs and have more frequent follow-up 
visits. A strength of our study was the use of sputum 
cultures to exclude tuberculosis at baseline. Some of the 
eﬀ ect of isoniazid preventive therapy reported in studies 
that did not rigorously exclude tuberculosis might have 
arisen as a result of the eﬀ ect of isoniazid monotherapy on 
subclinical disease.20
The beneﬁ t of isoniazid preventive therapy in 
individuals on antiretroviral therapy seemed to decrease 
gradually over time rather than rebound rapidly soon 
after cessation. However, our study was underpowered to 
assess duration of beneﬁ t beyond the study period. The 
risk of active tuberculosis decreases over time because of 
improvements in CD4 counts mediated by antiretroviral 
therapy,3 which might have masked loss of eﬀ ect of 
isoniazid preventive therapy after completion. Findings 
of studies of isoniazid preventive therapy in pre-
antiretroviral therapy cohorts have shown that 6 months 
of isoniazid preventive therapy has a short-term beneﬁ t.21,22 
A similar, but more pronounced, loss of eﬀ ect was seen in 
the 6 month isoniazid preventive therapy group of the 
BOTUSA study,8 in which 45% of the participants started 
antiretroviral therapy according to need during the study 
period.8 Longer courses (>6 months) of isoniazid 
preventive therapy for all individuals with HIV are now 
recommended by WHO.23 Our ﬁ ndings, together with 
those of the BOTUSA study, support the use of longer-
term isoniazid preventive therapy in individuals on 
antiretroviral therapy living in moderate or high incidence 
areas. However, in routine clinical practice, the risk of 
non-adherence and treatment discontinuations might be 
higher in individuals prescribed extended isoniazid 
preventive therapy than in those prescribed shorter 
courses.17
In our study participants on antiretroviral therapy with 
negative tuberculin skin test results beneﬁ ted more from 
isoniazid preventive therapy than participants with 
positive tuberculin skin tests. We recorded similar trends 
in eﬀ ect by interferon gamma release assay status. This 
ﬁ nding was unexpected because results of a meta-
analysis2 of randomised controlled trials of isoniazid 
preventive therapy without antiretroviral therapy showed 
signiﬁ cant beneﬁ t only in those with a positive tuberculin 
skin test. It is not clear why tuberculin skin test positive 
individuals not on antiretroviral therapy might beneﬁ t 
more from isoniazid preventive therapy than do 
individuals with tuberculin skin test negative results. 
Individuals who test negative might not beneﬁ t as much 
because they are not latently infected with M tuberculosis. 
However, in areas with a high prevalence of tuberculosis, 
many of the negative tuberculin skin test results in 
individuals with HIV are likely to be false negatives, 
especially in those with low CD4 counts.24 Isoniazid 
preventive therapy might be eﬀ ective in antiretroviral 
therapy-naive patients with a positive tuberculin skin test 
because eﬀ ective isoniazid preventive therapy needs 
some acquired immunity to M tuberculosis, for which 
tuberculin skin test is a crude measure. Isoniazid 
modiﬁ es the immune response to tuberculosis, 
potentially by releasing mycobacterial antigens.25 In 
individuals who have positive tuberculin skin tests, 
antiretroviral therapy is likely to augment pre-existing 
Panel: Research in context
Systematic review
We searched PubMed for systematic reviews, meta-analyses, and randomised 
controlled trials of the eﬃ  cacy of tuberculosis preventive therapy on incident 
tuberculosis in adults with HIV on combination antiretroviral therapy published 
between Jan 1, 1996, and Jan 1, 2014. We included the following search terms: 
“antiretroviral therapy” OR “HIV” AND “tuberculosis” AND “isoniazid” OR “preventive 
therapy”. We identiﬁ ed one recent meta-analysis,2 and four subsequent trials that were 
not included in the meta-analysis,8,9,17,18 one was a cluster randomised trial of a complex 
intervention.18 We did not identify any randomised controlled trials of tuberculosis 
preventive therapy in adults on concurrent antiretroviral therapy.
Interpretation
Findings of the meta-analysis showed that preventive therapy reduced incident tuberculosis 
in adults with HIV with positive tuberculin skin tests, but not in those with negative 
tuberculin skin tests.2 However, the placebo-controlled trials included in the meta-analysis 
were all from the pre-antiretroviral therapy era, or were done in areas before antiretroviral 
therapy access. Measurement of the eﬃ  cacy and safety of tuberculosis preventive therapy 
in people on antiretroviral therapy is important because antiretroviral therapy also reduces 
the risk of tuberculosis, toxic eﬀ ects  of preventive therapy might be enhanced, and because 
25·9 million of the estimated 35·3 million living with HIV in 2012, qualiﬁ ed for antiretroviral 
therapy according to 2013 WHO guidelines.19 Three subsequent trials compared longer 
duration isoniazid preventive therapy with other preventive therapy regimens.8,9,17 The three 
trials of longer duration isoniazid preventive therapy were done in antiretroviral therapy-
naive individuals (except for 2% of participants in the BOTUSA study8), with participants 
starting antiretroviral therapy according to clinical need during follow-up. 36 months 
isoniazid preventive therapy was more eﬀ ective than 6 months in the BOTUSA study, with 
the beneﬁ t restricted to those who were tuberculin skin tests positive,8 but no beneﬁ t was 
recorded in the other two trials with smaller sample sizes.9,17 In the BOTUSA study, 
antiretroviral therapy for 1 year reduced tuberculosis incidence by 50%. A cluster 
randomised trial18 found that improved tuberculosis screening and isoniazid preventive 
therapy reduced incident tuberculosis, which was independent of the eﬀ ects of 
concomitant antiretroviral therapy at baseline. 
12 months of isoniazid preventive therapy reduced the incidence of tuberculosis in 
individuals on antiretroviral therapy, was easy to implement in an antiretroviral 
therapy clinic, and was well tolerated. Unlike other studies, we found that participants 
on antiretroviral therapy with negative tuberculin skin test  or interferon gamma 
release assay beneﬁ ted more from isoniazid preventive therapy than test-positive 
participants. Until a more predictive test for latent tuberculosis infection or a 
multivariate algorithm that predicts beneﬁ t in the context of antiretroviral therapy is 
available, isoniazid preventive therapy should be recommended to all patients 
receiving antiretroviral therapy in moderate or high incidence areas irrespective of 
tuberculin skin test status. Future studies should explore improved diagnostics for 
latent tuberculosis infection, large-scale implementation of longer duration of 
isoniazid preventive therapy, or more sterilising preventive therapy regimens, in people 
on antiretroviral therapy. 
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immunity to M tuberculosis, and the incremental beneﬁ t 
of isoniazid preventive therapy might be small or non-
existent. By contrast, in individuals with negative 
tuberculin skin tests results, antiretroviral therapy 
improves acquired immunity to M tuberculosis in 
individuals who have been exposed to M tuberculosis, as 
shown by positive results on repeat skin test. Investigators 
of a recent Ugandan study26 reported a high negative to 
positive tuberculin skin test conversion rate 
of 30·9 per 100 person-years during the ﬁ rst 6 months 
after antiretroviral therapy initiation. Isoniazid preventive 
therapy might be eﬀ ective in this setting of early 
restoration of acquired immunity. In patients on 
antiretroviral therapy, the eﬃ  cacy of isoniazid preventive 
therapy might not be strongly linked to tuberculin skin 
test or interferon gamma release assay status.
More participants in the isoniazid group than the 
placebo group stopped taking the study drug because of 
adverse events, with a relative risk similar to that reported 
in the Cochrane meta-analysis2 of isoniazid preventive 
therapy trials in patients not yet started on antiretroviral 
therapy (RR 1·5, 95% CI 0·84–2·7 vs 1·66, 1·09–2·51). 
Additionally, we did not ﬁ nd strong evidence for increased 
risk of cessation of study drug because of toxic eﬀ ects in 
individuals newly starting antiretroviral therapy. These 
data suggest no additive toxic eﬀ ects of isoniazid 
preventive therapy in patients concurrently receiving 
antiretroviral therapy.
Our study had some limitations. First, the study did 
not have suﬃ  cient statistical power to show clear 
diﬀ erences in eﬀ ect estimates by tuberculin skin test or 
interferon gamma release assay status, or to establish 
the duration of beneﬁ t of isoniazid preventive therapy 
in individuals on antiretroviral therapy, for which a 
larger sample size or longer duration of follow up would 
have been needed. Second, although we aimed to 
conﬁ rm as many cases of incident tuberculosis as 
possible with culture at the study clinic, 39% of cases 
were diagnosed at satellite clinics where diagnostic 
conﬁ rmation might not have been as rigorous. Thus, 
the incidence of culture-conﬁ rmed tuberculosis might 
have been underestimated. Third, we did not repeat 
tuberculin skin tests and interferon gamma release 
assays early in the study. The prospective usefulness of 
one test result obtained at screening might be reduced 
with increasing study follow-up and time on 
antiretroviral therapy. Repeat testing after several 
months of antiretroviral therapy might have allowed 
more accurate measurement of the presence of latent 
tuberculosis infection.26–31 Fourth, the rate of tuberculosis 
in the placebo group was lower than the rate assumed, 
which we had estimated from two local cohort studies32,33 
available to us when the study started. Possible 
explanations for the lower than expected tuberculosis 
incidence are high case ascertainment by screening 
with sputum cultures, which decreases tuberculosis 
incidence after start of antiretroviral therapy,34 and 
increased CD4 counts at antiretroviral therapy 
initiation,35 which is the most important risk factor for 
incident tuberculosis after antiretroviral therapy 
initiation.36 However, person-years were higher than we 
had assumed because loss to follow-up was lower than 
expected and duration of follow-up was longer than 
planned because of slow recruitment. Our study 
had 80% statistical power for the recorded eﬀ ect size 
of 37% of isoniazid preventive therapy for the primary 
endpoint, suggesting that the longer period of 
observation compensated for the lower than expected 
tuberculosis incidence. Fifth, ﬁ ndings of our study 
showed a more modest eﬀ ect than previously shown in 
mostly observational studies.5–7 Issues with methods in 
previous studies prevented an independent assessment 
of the eﬀ ect of isoniazid preventive therapy with 
antiretroviral therapy.5–8 The small eﬀ ects described, and 
the resultant high rate of tuberculosis in the intervention 
group, suggest antiretroviral therapy plus isoniazid 
preventive therapy alone might not be adequate to 
control tuberculosis at the population level. Sixth, our 
study results might not be generalisable to settings of 
low tuberculosis incidence where background rates of 
M tuberculosis exposure are low. Finally, we did a 
pragmatic trial in a busy antiretroviral therapy and 
tuberculosis integrated clinic; study procedures would 
probably have been more rigorous in a dedicated fully 
staﬀ ed study clinic, but doing the study in a busy 
antiretroviral therapy clinic with minimum additional 
staﬃ  ng allowed us to assess implementation of 
isoniazid preventive therapy.
In summary, 12 months of isoniazid preventive therapy 
reduced the incidence of tuberculosis in individuals 
infected with HIV-1 established on antiretroviral therapy 
or newly starting antiretroviral therapy and seemed well 
tolerated. In this high incidence setting, individuals on 
antiretroviral therapy who have negative tuberculin skin 
test or interferon gamma release assay might also beneﬁ t 
from isoniazid preventive therapy. Implementation of 
isoniazid preventive therapy is feasible in busy 
antiretroviral therapy clinics in settings with high rates of 
HIV and tuberculosis comorbidity.
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